Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Rapport Therapeutics
AddedFeb 13, 2024
UpdatedJun 18, 2026
Rapport Therapeutics

Rapport Therapeutics

Series B

Rapport Therapeutics: A clinical-stage biotech firm developing precision medicines for neurological disorders.

HQ
Boston, MA, US
Founded
2022
Overview
Compare
Fundraising
Employees

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company emphasizes relationships defined by understanding, communication, teamwork, and trust, aiming to transform patient care through innovative treatments.

Rapport Therapeutics has made significant strides in the biotech industry, focusing on precision medicine to address complex neurological conditions. Its impact is marked by advancing clinical trials and fostering a collaborative environment that drives scientific breakthroughs.

Rapport Therapeutics - Similar Companies

Rapalogix Health logo

Rapalogix Health

Neuron23 logo

Neuron23

Nido Biosciences logo

Nido Biosciences

nidobio.com

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

Moma Therapeutics logo

Moma Therapeutics

Alphina Therapeutics logo

Alphina Therapeutics

Odyssey Therapeutics logo

Odyssey Therapeutics

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Neuraptive Therapeutics logo

Neuraptive Therapeutics

neuraptive.com

Praxis Precision Medicines logo

Praxis Precision Medicines

Harmony Biosciences logo

Harmony Biosciences

Precision IBD logo

Precision IBD

Encoded Therapeutics logo

Encoded Therapeutics

ProFound Therapeutics logo

ProFound Therapeutics

profoundtx.com

Cogent Biosciences logo

Cogent Biosciences

cogentbio.com

Rapport Therapeutics - Quick Facts

Who are Rapport Therapeutics' competitors?

Companies similar to Rapport Therapeutics include Rapalogix Health, Neuron23, Nido Biosciences and Nested Therapeutics.

When was Rapport Therapeutics founded?

Rapport Therapeutics was founded in 2022.

Where is Rapport Therapeutics' headquarters located?

Rapport Therapeutics' headquarters is located in Boston, MA, US.

When was Rapport Therapeutics' last funding round?

Rapport Therapeutics' most recent funding round was for $150M (USD) in August 2023.

How much has Rapport Therapeutics raised to-date?

As of Aug 23, 2023, Rapport Therapeutics has raised a total of $250M (USD).

How many employees does Rapport Therapeutics have?

Rapport Therapeutics has 36 employees as of Feb 4, 2024.

Rapport Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Precision Medicines
Tags
  • Healthtech
Unique IDs
  • ein: 880724208
  • secCik: 0002012593
  • ticker: RAPP
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified